Skip to content
Research Article Open access CC BY 4.0

N-AcetylCysteine, Hypertonic Saline and Mannitol in Chronic Respiratory Diseases; Efficiency and Safety Considerations

M. Shohrati, A. Taheri, H. Borna, M. Ghanei

Journal of Advances in Medical and Pharmaceutical Sciences · pp. 1–12 · Published 31 Dec 2016

10.9734/JAMPS/2016/30622

Abstract

Chronic Respiratory Diseases (CRDs) are a group of long-lasting malfunctions of respiratory system. Almost all of them, are not curable and pharmacological interventions are life-time. Because of the chronic use of therapies, safety of the interventions are as important as efficacy of them. According to the guidelines of therapy, inhaled corticosteroids, inhaled beta2-agonists, methylxanthines and phosphodiesterase inhibitors are main current agents for the treatment of CRDs, while there exists a wide range of adverse reactions during long-time use of the drugs. Adding efficient agents with less side effects could be beneficial. In this article we review the efficacy and safety profile of N-AcetylCysteine, Hypertonic Saline and Mannitol on different types of CRDs, and recommend their use in the management of CRDs. Methods: All information was collected from articles of international medical journals and online databases using key words below. PubMed, Cochrane library, Scopus, Google Scholar, and Clinicaltrial.gov databases were searched for literature published between January 2000 and December 2015. Conclusion: Adding these agents to first line of therapy for CRDs could be beneficial, while more studies are needed to support their use in clinical setting.  

Chronic respiratory disease N-AcetylCysteine hypertonic saline mannitol

References (30)

  1. 1 GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION [DOI]
  2. 2 Fine Particulate Air Pollution and Hospital Admission for Cardiovascular and Respiratory Diseases [DOI]
  3. 3 High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis [DOI]
  4. 4 Systemic side effects of inhaled corticosteroids in patients with asthma [DOI]
  5. 5 Management of bronchiectasis in adults [DOI]
  6. 6 Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials [DOI]
  7. 7 Quality of Life in Patients With Chronic Obstructive Pulmonary Disease and Comorbid Anxiety or Depression [DOI]
  8. 8 High-dose oral N -acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis [DOI]
  9. 9 A Comparison of Clinically Important Differences in Health‐Related Quality of Life for Patients with Chronic Lung Disease, Asthma, or Heart Disease [DOI]
  10. 10 N-acetylcysteine inhibit biofilms produced by Pseudomonas aeruginosa [DOI]
  11. 11 High-Dose N-Acetylcysteine in Stable COPD [DOI]
  12. 12 Nebulized Hypertonic Saline in the Treatment of Viral Bronchiolitis in Infants [DOI]
  13. 13 Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial [DOI]
  14. 14 Inhaled Mannitol Improves Lung Function in Cystic Fibrosis [DOI]
  15. 15 Traffic-related air pollution associated with prevalence of asthma and COPD/chronic bronchitis. A cross-sectional study in Southern Sweden [DOI]
  16. 16 Long-Term Inhaled Dry Powder Mannitol in Cystic Fibrosis: An International Randomized Study [DOI]
  17. 17 Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: Effect on lung function, health status and sputum [DOI]
  18. 18 Nebulized Hypertonic Saline Decreases IL-8 in Sputum of Patients with Cystic Fibrosis [DOI]
  19. 19 The 24-h Effect of Mannitol on the Clearance of Mucus in Patients With Bronchiectasis [DOI]
  20. 20 Hyperosmolar Agents and Clearance of Mucus in the Diseased Airway [DOI]
  21. 21 Mechanisms and applications of hypertonic saline [DOI]
  22. 22 Inhaled Mannitol Improves the Hydration and Surface Properties of Sputum in Patients With Cystic Fibrosis [DOI]
  23. 23 Effect of N-Acetylcysteine on Air Trapping in COPD [DOI]
  24. 24 Bronchiectasis: New Approaches to Diagnosis and Management [DOI]
  25. 25 Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion* [DOI]
  26. 26 Symptoms and signs of respiratory disease [DOI]
  27. 27 Theophylline‐associated seizures and their clinical characterizations [DOI]
  28. 28 Pharmacotherapy for bronchiectasis [DOI]
  29. 29 High-Dose N -Acetylcysteine in Chronic Obstructive Pulmonary Disease, Prone Positioning in Acute Respiratory Distress Syndrome, and Continuous Positive Airway Pressure and Exhaled Nitric Oxide in Obstructive Sleep Apnea [DOI]
  30. 30 Chronic respiratory diseases. [DOI]

Cited by 2

Mucus Hypersecretion, Hyperconcentration and Chronic Bronchitis

M. Kesimer, M. Drummond, R. Boucher · Reference Module in Biomedical Sciences · 2021

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

47

Page views

0

PDF downloads

12

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.